H.C. Wainwright double downgraded Synlogic to Sell from Buy without a price target after the company announced its decision to discontinue the pivotal, Phase 3 SYNPHENY-3 study of labafenogene marselecobac as a potential treatment for phenylketonuria. The firm says the company has suffered a “sudden and stunning implosion.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on SYBX:
- Synlogic Announces Decision to Discontinue Synpheny-3 Study and Provides Corporate Update
- Synlogic Announces Publication of Preclinical and Clinical Data for SYNB1353 as a Potential Treatment for Classical Homocystinuria
- Synlogic reports publication of prelinical, clinical data for SYNB1353
- Synlogic Provides Corporate Update and Outlook for 2024
- Synlogic provides corporate update, outlook for 2024
